Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
53 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) - Pipeline Review, H2 2016', provides in depth analysis on Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) targeted pipeline therapeutics. The report provides comprehensive information on the Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) - The report reviews Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) targeted therapeutics and enlists all their major and minor projects - The report assesses Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) Overview 7 Therapeutics Development 8 Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) - Products under Development by Stage of Development 8 Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) - Products under Development by Therapy Area 9 Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) - Products under Development by Indication 10 Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) - Products under Development by Companies 13 Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) - Products under Development by Universities/Institutes 15 Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) - Therapeutics Assessment 17 Assessment by Monotherapy/Combination Products 17 Assessment by Mechanism of Action 18 Assessment by Route of Administration 19 Assessment by Molecule Type 21 Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) - Companies Involved in Therapeutics Development 22 Ensemble Therapeutics Corporation 22 NeuroVive Pharmaceutical AB 23 Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) - Drug Profiles 24 cyclosporine - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 cyclosporine - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 NVP-014 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 NVP-015 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 NVP-018 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 NVP-019 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 Small Molecule to Inhibit Cyclophilin D for Acute Pancreatitis - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 Small Molecules to Inhibit Cyclophilin D for Cardiovascular and Central Nervous System - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) - Dormant Projects 37 Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) - Discontinued Products 39 Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) - Featured News & Press Releases 40 Jun 07, 2016: NeuroVive announces CiPRICS study completes enrolment 40 Apr 28, 2016: NeuroVive's R&D Team to Present Research Progress at Mitochondrial Medicine Conference 41 Mar 14, 2016: NeuroVive announces the CiPRICS study enrols 100 patients and reports favourable safety evaluation 41 Nov 19, 2015: NeuroVive reports favourable safety evaluation in Phase II acute kidney injury study 42 Nov 02, 2015: NeuroVive Pharmaceutical: NeuroVive Presents Findings Targeting Complex I Deficiency at World Mitochondria Congress 43 Oct 28, 2015: NeuroVive Aims to Find Path Forward in Antiviral Development Following Discontinuation of OCB-030 Preclinical Program by Arbutus 43 Aug 30, 2015: Cyclosporine Does Not Improve Outcomes After PCI 44 Jun 01, 2015: Neurovive Reports Topline Results of Phase III CIRCUS Study in Acute Myocardial Infarction 44 May 25, 2015: Neurovive Pharmaceutical: Topline Result of Phase III Study of Ciclomulsion in Acute Myocardial Infarction Expected This Quarter 46 May 07, 2015: Neurovive Pharmaceutical: Published Data Indicates Protective Effect of Cyclosporine in Patients with Stroke 46 Apr 27, 2015: FIrst Patient Enrolled in Clinical Phase II Study for Kidney Protection During Heart Surgery 47 Apr 21, 2015: Clinical Phase II Study with NeuroSTAT for Traumatic Brain Injury Passes Safety Evaluation 48 Apr 17, 2015: Development of NVP014 for the treatment of stroke enters new phase in collaboration with Isomerase Therapeutics 49 Dec 02, 2014: NeuroVive and Skane University Hospital initiate collaboration on clinical phase II study on kidney protection during heart surgery 50 Aug 14, 2014: Neurovive Pharmaceutical Announces Enrollment To Phase II Study On NeuroSTAT Continues 51 Appendix 52 Methodology 52 Coverage 52 Secondary Research 52 Primary Research 52 Expert Panel Validation 52 Contact Us 52 Disclaimer 5
List of Tables
Number of Products under Development for, H2 2016 8 Number of Products under Development by Therapy Area, H2 2016 9 Number of Products under Development by Indication, H2 2016 10 Comparative Analysis by Late Stage Development, H2 2016 11 Comparative Analysis by Early Stage Products, H2 2016 12 Number of Products under Development by Companies, H2 2016 13 Products under Development by Companies, H2 2016 14 Number of Products under Investigation by Universities/Institutes, H2 2016 15 Products under Investigation by Universities/Institutes, H2 2016 16 Assessment by Monotherapy/Combination Products, H2 2016 17 Number of Products by Stage and Mechanism of Action, H2 2016 18 Number of Products by Stage and Route of Administration, H2 2016 20 Number of Products by Stage and Molecule Type, H2 2016 21 Pipeline by Ensemble Therapeutics Corporation, H2 2016 22 Pipeline by NeuroVive Pharmaceutical AB, H2 2016 23 Dormant Projects, H2 2016 37 Dormant Projects (Contd..1), H2 2016 38 Discontinued Products, H2 2016 39
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
